Fractyl Health opened at $0.88, in line with its previous close of $0.88. In the last trading session, the stock traded between $0.83 and $0.91. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Fractyl Health is now worth
$ 6.45
Resulting in a loss of
$ 93.55 (93.55%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
80%
Hold
20%
Sell
0%
Markets Today
Today's Change
$-0.05 (-5.92%)
Day High
$0.91
Day Low
$0.83
Day Open
$0.88
Prev Close
$0.88
Volume
1,63,442
1W Return
-14.80%
1M Return
-81.15%
3M Return
19.28%
6M Return
7.80%
1Y Return
-24.64%
Fundamentals
Market Cap ($ Mn)
11
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-3,082.04%
ROCE
-182.04%
EPS (TTM)
$-1.93
Investment Returns
1 Week
-14.80%
1 Month
-81.15%
3 Months
19.28%
6 Months
7.80%
9 Months
91.41%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
20Oct
Canaccord Genuity cuts Fractyl Health price target to $39, keeps Buy rating
Canaccord Genuity maintains a Buy rating on Fractyl Health. Price target lowered from $96 to $39 by analyst Whitney Ijem. The reduction amounts to a $57 decrease in the projected share price.
23 days ago
20Oct
Fractyl Health class action deadline set for October 20, 2026
Fractyl Health faces a securities class action with a lead plaintiff deadline of October 20, 2026. Stock declined 74.86% over two sessions in January 2026 following clinical data disclosure. Moore Law PLLC urges shareholders to contact the firm for potential monetary damages. Complaint alleges misleading statements about Revita device efficacy and site-level issues.
24 days ago
19Oct
Morgan Stanley lowers Fractyl Health price target to $4
Morgan Stanley lowered Fractyl Health's price target from $24 to $4. The firm maintained an Equal-Weight rating on the stock. Analyst Michael Ulz issued the revised price target.
24 days ago
16Oct
Fractyl Health shares drop 50% despite positive REMAIN-1 trial data
Fractyl Health shares fell nearly 50% to $2.11 despite positive REMAIN-1 trial results. Pivotal Cohort showed 80% weight loss retention vs 67% in sham arm (p=0.0023). Ongoing class action lawsuit alleges misleading disclosures regarding earlier Midpoint Cohort data. Morgan Stanley cut price target to $2 and probability of success to 35% after prior setbacks.
